摘要
重度哮喘是哮喘患者致残、致死的主要原因,具有高度的疾病未来风险,也造成了严重的社会经济负担。气道炎症异质性明显、气道重塑严重、遗传因素影响、糖皮质激素反应性降低等病理生理学机制以及众多影响哮喘控制因素的存在,导致重度哮喘治疗尤为困难。近年来,随着对哮喘发病机制认识的不断深入,特别是针对2型炎症靶点的生物制剂的研发,为重度哮喘患者的治疗开辟了新的途径。但如何对重度哮喘患者进行正确的诊断和评估,如何进行治疗选择,仍然是临床实践存在的困惑与挑战。本专家共识在2017年发表的《重症哮喘诊断与处理中国专家共识》基础上,结合最新国内外研究进展,围绕重度哮喘的定义、发病机制、诊断与评估、治疗等方面进行了更新,特别是对2型炎症生物制剂的治疗推荐,为重度哮喘的个体化诊疗提供参考。
Severe asthma is the main cause of disability and death in patients with asthma,with a high risk of future disease,but also caused serious social and economic burden.The pathophysiological mechanisms such as obvious heterogeneity of airway inflammation,severe airway remodeling,influence of genetic factors,decreased glucocorticoid responsiveness,and many factors affecting asthma control make the treatment of severe asthma particularly difficult.In recent years,with the deepening of the understanding of the pathogenesis of asthma,especially the development of biologics targeting type 2 inflammation,a new approach has been opened up for the treatment of patients with severe asthma.How to correctly diagnose and evaluate severe asthma patients and how to choose treatment are still the perplexity and challenge in clinical practice.This expert consensus is based on the"Chinese Expert Consensus on the Diagnosis and Management of Severe Asthma"published in 2017 and combined with the latest research progress at home and abroad,and is updated on the definition,pathogenesis,diagnosis and evaluation,and treatment of severe asthma,especially the treatment recommendation for type 2 inflammatory biologics,so as to provide reference for the individualized diagnosis and treatment of severe asthma.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2024年第20期1759-1789,共31页
National Medical Journal of China
基金
国家自然科学基金(82170027)
中国医药教育协会2022重大科学攻关问题和医药技术难题科研课题(2022KTZ001)
关键词
哮喘
重度哮喘
2型炎症
2型哮喘
生物制剂
Asthma
Severe asthma
Type 2 inflammation
Type 2 asthma
Biologics
